人乳头瘤病毒相关口咽癌筛查的考量:综述
本文综述HPV阳性口咽癌筛查的证据。该病负担显著且预计上升,高危人群为有多个性伴侣的中老年男性;早期检测可能获益,但现有筛查试验敏感性和特异性不足,筛查获益与危害未知,目前不支持开展筛查。
要点
- HPV阳性口咽癌负担显著且预计上升,二级预防值得探索。
- 现有筛查试验敏感性和特异性不足,筛查获益与危害未知。
- 目前不支持开展HPV阳性口咽癌筛查。
核心结论
- 目前不支持开展HPV阳性口咽癌筛查。
- 需进一步探索二级预防干预,并推进生物标志物发现及大规模临床试验。
研究设计与样本
- 综述,评估HPV阳性口咽癌筛查相关证据,未报告检索范围与样本量。
主要发现
- 口咽癌终生风险男性0.7%、女性0.2%,且预计上升。
- HPV阳性口咽癌疾病负担显著,多数患者接受高并发症的多模式治疗并产生高费用。
- 高危人群为有较多终生阴道或口腔性伴侣的中老年男性。
- I期HPV阳性口咽癌患者4年总生存率为87%,相当部分可接受并发症较少的单模式治疗。
- 现有筛查试验在最高危人群当前发病率下敏感性和特异性不足,筛查获益与危害未知。
临床怎么用
- 目前不应开展HPV阳性口咽癌筛查。
- 临床应关注高危人群,但需等待筛查获益与危害的进一步证据。
局限性
- 筛查获益与危害未知。
- 现有筛查试验敏感性和特异性不足。
- 需大规模临床试验和严格评估以指导临床实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) is anticipated to rise over the next few decades until the effects of prophylactic vaccination are realized, which highlights the potential importance of secondary prevention. The objective of this review is to evaluate the evidence associated with screening for HPV-positive OPC. OBSERVATIONS: Evaluation of a potential clinical preventive screening service requires characterization of the disease burden, the at-risk target screening population, screening tests, treatment, and screening benefits and harms. The lifetime risk of OPC is 0.7% for men and 0.2% for women and is expected to increase. The disease burden of HPV-positive OPC is substantial; most patients undergo morbid multimodality treatment and incur high costs in the process. Middle-aged and older adult men with elevated number of lifetime vaginal or oral sex partners are at highest risk. Patients may benefit from early detection of the disease-the 4-year overall survival of patients with stage I HPV-positive OPC is 87%, a considerable portion of whom are eligible for less morbid single-modality therapy. However, available screening tests are insufficiently sensitive and specific considering the current HPV-positive OPC incidence rates in the most at-risk patients. Further, the benefits and harms of screening for HPV-positive OPC are unknown. CONCLUSIONS AND RELEVANCE: The current and projected future population-level burden of HPV-positive OPC supports further exploration of secondary preventive interventions. However, screening for HPV-positive OPC is not currently justified. Advances in biomarker discovery and improved characterization of (1) a highly at-risk, target screening population and (2) the benefits and harms of screening will be necessary. Large-scale clinical trials and rigorous evaluation of how to best implement this service into clinical practice will also be needed.
引用
- Day AT, Fakhry C, Tiro JA, et al. Considerations in Human Papillomavirus-Associated Oropharyngeal Cancer Screening: A Review. JAMA Otolaryngol Head Neck Surg. 2020. PMID: 32379293. doi:10.1001/jamaoto.2019.4811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。